Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 41
Making Better Drugs for Children with Cancer REFERENCES American Cancer Society. 2004. Cancer Facts and Figures, 2004. Atlanta, GA: American Cancer Society. Bumol TF, Watanabe AM. 2001. Genetic information, genomic technologies, and the future of drug discovery. JAMA 285(5):551–555. Butte AJ, Tamayo P, Slonim D, Golub TR, Kohane IS. 2000. Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc Natl Acad Sci U S A 97(22):12182–12186. Connors T. 1996. Anticancer drug development: The way forward. Oncologist 1(3):180–181. Eisenhauer EA. 1998. Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism. The Michel Clavel lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, Holland, June 16–19, 1998. Annals of Oncology 9(10):1047–1052. Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, Grever MR. 1995. In vivo cultivation of tumor cells in hollow fibers. Life Sciences 57(2):131–141. Houghton PJ, Stewart CF, Thompson J, Santana VM, Furman WL, Friedman HS. 1998. Preclinical and clinical results with irinotecan: Extending principles learned in model systems to clinical trials design. Oncology 12(8 Suppl.): 84–93. IOM (Institute of Medicine). 2000. Rational Therapeutics for Infants and Children: Workshop Summary. Washington, DC: National Academy Press. IOM. 2003. Child Cancer Survivorship: Improving Care and Quality of Life. Washington, DC: The National Academies Press. IOM. 2004. The Ethical Conduct of Clinical Research Involving Children. Washington, DC: The National Academies Press. Jemal A, Clegg LX, Ward E, Ries LAG, Wu X, Jamison PM, Wingo PA, Howe HL, Anderson RN, Edwards BK. 2004. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 101(1):3–27. Kerbel RS. 1998/99. What is the optimal rodent model for anti-tumor drug testing? Cancer & Metastasis Reviews 17(3):301–304. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. 2000. Proteasome inhibition measurements: Clinical application. Clin Chem 46(5):673–683. Minino AM, Smith BL. 2001. Deaths: Preliminary data for 2000. National Vital Statistics Reports 49(12):1–40. National Cancer Institute. 2004. PDQ® Cancer Information Summaries: Pediatric Treatment. Available: http://www.nci.nih.gov/cancerinfo/pdq/pediatrictreatment [accessed December 2004]. Pearce HL. 1995. Anticancer drug development at Lilly Research Laboratories. Annals of Oncology 6(Suppl. 1):S55–S62. Pediatric AIDS Foundation. Children’s groups appeal pediatric drug testing decision. Pediatric AIDS Foundation News December 16, 2002. Available: http://www.pedaids.org/december16_2002_release.html [accessed February 17, 2005]. Pervan M, Pajonk F, Sun JR, Withers HR, McBride WH. 2001. Molecular pathways that modify tumor radiation response. American Journal of Clinical Oncology 24(5):481–485. PhRMA (Pharmaceutical Research and Manufacturers of America). 2004. Medicines in Development for Children 2004. Washington, DC: PhRMA. Phillips RM, Pearce J, Loadman PM, Bibby MC, Cooper PA, Swaine DJ, Double JA. 1998. Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: Implications for anticancer drug screening programs. Cancer Res 58(23):5263–5266.
OCR for page 42
Making Better Drugs for Children with Cancer Pizzo PA, Poplack DG, eds. 2001. Principles and Practice of Pediatric Oncology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins. Powell DA, Nahata MC. 1982. Chloramphenicol: New perspectives on an old drug. Drug Intelligence & Clinical Pharmacy 16(4):295–300. Reis BY, Butte AS, Kohane IS. 2001. Extracting knowledge from dynamics in gene expression. J Biomed Inform 34(1):15–27. Ries LAG, Eisner MP, Kosary CL, et al. 2002. SEER Cancer Statistics Review, 1973–1999. Bethesda, MD: National Cancer Institute. Smith A. 2002. Screening for drug discovery: The leading question. Nature 418(6896):453–459. U.S. Cancer Statistics Working Group. 2004. United States Cancer Statistics: 2001 Incidence and Mortality. Atlanta, GA: Centers for Disease Control and Prevention and National Cancer Institute. U.S. District Court for the District of Columbia. 2002. Association of American Physicians and Surgeons, Inc., et al., Plaintiffs, v. United States Food and Drug Administration, et al., Defendants, Civil Action 00-02898 (HHK). Memorandum Opinion. October 17, 2002. Available: http://www.dcd.uscourts.gov/00-02898.pdf. U.S. Food and Drug Administration. 2004. What’s New by Date. [Online]. Available: http://www.fda.gov/cder/whatsnew.htm [accessed January 5, 2005]. U.S. Food and Drug Administration. 2005. Pediatric exclusivity statistics as of January 31, 2005. Available: http://www.fda.gov/cder/pediatric/wrstats.htm [accessed February 17, 2005]. Von Hoff DD. 1998. There are no bad anticancer agents, only bad clinical trial designs—twenty-first Richard and Hinda Rosenthal Foundation award lecture. Clinical Cancer Research 4(5):1079–1086.
Representative terms from entire chapter: